EirGenix Valuation

6589 Stock  TWD 76.60  6.30  7.60%   
At this time, the firm appears to be overvalued. EirGenix shows a prevailing Real Value of NT$72.01 per share. The current price of the firm is NT$76.6. Our model computes the value of EirGenix from reviewing the firm fundamentals such as Current Valuation of 39.51 B, insignificant profit margin, and Shares Outstanding of 304.26 M as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
76.60
Please note that EirGenix's price fluctuation is very steady at this time. Calculation of the real value of EirGenix is based on 3 months time horizon. Increasing EirGenix's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the EirGenix stock is determined by what a typical buyer is willing to pay for full or partial control of EirGenix. Since EirGenix is currently traded on the exchange, buyers and sellers on that exchange determine the market value of EirGenix Stock. However, EirGenix's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  76.6 Real  72.01 Hype  82.9 Naive  87.06
The intrinsic value of EirGenix's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence EirGenix's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
72.01
Real Value
91.19
Upside
Estimating the potential upside or downside of EirGenix helps investors to forecast how EirGenix stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of EirGenix more accurately as focusing exclusively on EirGenix's fundamentals will not take into account other important factors:
Bollinger
Band Projection (param)
LowerMiddle BandUpper
80.8887.7794.65
Details
Hype
Prediction
LowEstimatedHigh
80.8482.9084.96
Details
Naive
Forecast
LowNext ValueHigh
84.9987.0689.12
Details

EirGenix Total Value Analysis

EirGenix is presently anticipated to have takeover price of 39.51 B with market capitalization of 36.97 B, debt of 0, and cash on hands of 626.11 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the EirGenix fundamentals before making investing decisions based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
39.51 B
36.97 B
0
626.11 M

EirGenix Investor Information

About 33.0% of the company shares are owned by insiders or employees . The book value of EirGenix was presently reported as 35.17. The company had not issued any dividends in recent years. Based on the key measurements obtained from EirGenix's financial statements, EirGenix is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.

EirGenix Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. EirGenix has an asset utilization ratio of 14.84 percent. This indicates that the Company is making NT$0.15 for each dollar of assets. An increasing asset utilization means that EirGenix is more efficient with each dollar of assets it utilizes for everyday operations.

EirGenix Ownership Allocation

EirGenix holds a total of 304.26 Million outstanding shares. EirGenix retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

EirGenix Profitability Analysis

The company reported the revenue of 1.7 B. Net Loss for the year was (42.58 M) with profit before overhead, payroll, taxes, and interest of 1.09 B.

About EirGenix Valuation

Our relative valuation model uses a comparative analysis of EirGenix. We calculate exposure to EirGenix's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of EirGenix's related companies.
EirGenix Inc. operates as a contract development and manufacturing company worldwide. Its services include cell line development, process development, analytical sciences and quality control, cGMP manufacturing, and antibody drug conjugate. EIRGENIX INC operates under Biotechnology classification in Taiwan and is traded on Taiwan OTC Exchange. It employs 179 people.

8 Steps to conduct EirGenix's Valuation Analysis

Company's valuation is the process of determining the worth of any company in monetary terms. It estimates EirGenix's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct EirGenix's valuation analysis, follow these 8 steps:
  • Gather financial information: Obtain EirGenix's financial statements, including balance sheets, income statements, and cash flow statements.
  • Determine EirGenix's revenue streams: Identify EirGenix's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
  • Analyze market data: Research EirGenix's industry and market trends, including the size of the market, growth rate, and competition.
  • Establish EirGenix's growth potential: Evaluate EirGenix's management, business model, and growth potential.
  • Determine EirGenix's financial performance: Analyze its financial statements to assess its historical performance and future potential.
  • Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
  • Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate EirGenix's estimated value.
  • Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Note: This is a general outline, and different approaches and methods may be used depending on the type and size of the company being valued. We also recomment to seek professional assistance to ensure accuracy.

Additional Tools for EirGenix Stock Analysis

When running EirGenix's price analysis, check to measure EirGenix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EirGenix is operating at the current time. Most of EirGenix's value examination focuses on studying past and present price action to predict the probability of EirGenix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EirGenix's price. Additionally, you may evaluate how the addition of EirGenix to your portfolios can decrease your overall portfolio volatility.